94V Stock Overview
A clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Aptahem AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.067 |
| 52 Week High | SEK 0.36 |
| 52 Week Low | SEK 0.04 |
| Beta | -0.074 |
| 1 Month Change | -28.39% |
| 3 Month Change | -43.56% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -52.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 94V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0.6% | -3.2% | 2.7% |
| 1Y | n/a | -7.9% | 17.0% |
Return vs Industry: Insufficient data to determine how 94V performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 94V performed against the German Market.
Price Volatility
| 94V volatility | |
|---|---|
| 94V Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 94V's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 94V's weekly volatility has decreased from 49% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 4 | Mikael Lindstam | www.aptahem.com |
Aptahem AB (publ), a clinical stage biotechnology company, develops aptamer-based pharmaceuticals for the treatment of acute life-threatening conditions. Its principal pharmaceutical candidate is Apta-1, which is in preclinical stage to prevent mortality rate caused by organ and tissue damage in sepsis patients. The company has collaborations with various academic groups, including Consortium with Orebro University, Seattle Children’s Research Institute, and University Health Network.
Aptahem AB (publ) Fundamentals Summary
| 94V fundamental statistics | |
|---|---|
| Market cap | €980.19k |
| Earnings (TTM) | -€887.19k |
| Revenue (TTM) | €172.38k |
5.7x
P/S Ratio-1.1x
P/E RatioIs 94V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 94V income statement (TTM) | |
|---|---|
| Revenue | SEK 1.93m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 1.93m |
| Other Expenses | SEK 11.89m |
| Earnings | -SEK 9.96m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.80 |
| Gross Margin | 100.00% |
| Net Profit Margin | -514.66% |
| Debt/Equity Ratio | 0% |
How did 94V perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 14:57 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aptahem AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.